GRYPHON BIO INC
sgp130-Fc bioconjugate therapeutic targeting IL-6 trans-signaling to improve neurorecovery in traumatic brain injury
- Sector
- Biotech
- Headquarters
- South San Francisco, CA
- Total capital
- $4M
- Federal grants
- $3.2M
- 5 awards · 2021–2025
- Rank in peer group#316 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $749K
- 1 award · Defense
- Rank in Biotech#207 of 4373
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of Novel sgp130-Fc Bioconjugates for TBI$1.2M
- Federal grantHealth and Human S · Phase I · Development of Novel sgp130-Fc Bioconjugates for TBI$485K
- Federal grantHealth and Human S · Phase II · Development of Novel sgp130-Fc Bioconjugates for TBI$485K
- Federal contractDefense · New Research And Development Contract Award For The Feasibility Study Of A Single Platform Solution For Blood Testing Of Traumatic Brain Injury Biomarkers For The Congressionally Directed Medical Research Program Office$749K
- Federal grantHealth and Human S · Phase I · Temporal Biomarker-Powered Immunotherapy Targeting GFAP for Traumatic Brain Injury$499K
- Federal grantHealth and Human S · Phase II · Temporal Biomarker-Powered Immunotherapy Targeting GFAP for Traumatic Brain Injury$499K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Linked publications#17 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 5- PendingBiomarker Panel For Brain Specific Abnormal Neurological Conditions Using Biofluid SamplesUSPTOApplication 19129782
- PendingSampling And Testing Process For Brain Health And Injury From Various Sources And Correlations TherebetweenUSPTOApplication PCTUS2025032634
- PendingSampling And Testing Solution For Brain Health And Injury From Various Sources And Correlations TherebetweenUSPTOApplication 63657396
Show all 5 patent records
- Biomarker Panel For Brain Specific Abnormal Neurological Conditions Using Biofluid SamplesJun 25, 2026 · Application 19129782Pending
- Sampling And Testing Process For Brain Health And Injury From Various Sources And Correlations TherebetweenApplication PCTUS2025032634Pending
- Sampling And Testing Solution For Brain Health And Injury From Various Sources And Correlations TherebetweenApplication 63657396Pending
- Biomarker Panel For Brain Specific Abnormal Neurological Conditions Using Biofluid SamplesApplication PCTUS2023080001Pending
- Blood Biomarker Panel For Brain Specific Abnormal Neurological Conditions Using Capillary Blood SamplesApplication 63425761Pending
Recent research by its founders
- The game changer: UCH-L1 and GFAP-based blood test as the first marketed in vitro diagnostic test for mild traumatic brain injury202455 cites
- Functional Selection of Tau Oligomerization‐Inhibiting Aptamers202425 cites
- Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development202419 cites
Related companies, and why
- GenomaticaSimilar federal contract value in Biotech · $761K in contracts
- ATUX ISKAY GROUP LLCSimilar federal contract value in Biotech · $755K in contracts
- Rigel PharmaceuticalsSimilar federal contract value in Biotech · $750K in contracts
- RenBio, Inc.Similar federal contract value in Biotech · $749K in contracts
- GEN1E LIFESCIENCES INC.Similar federal contract value in Biotech · $749K in contracts
- GALEN BIOTECHNOLOGIES, LLCSimilar federal contract value in Biotech · $727K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .